Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:1115 |
Name | sarcoma |
Definition | A cell type cancer that has_material_basis_in abnormally proliferating cells derives from embryonic mesoderm. |
Source | DiseaseOntology.org |
Alt Ids | DOID:3936 |
Path | disease disease of cellular proliferation cancer cell type cancer sarcoma |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00356031 | Phase II | Bevacizumab | Bevacizumab and Radiation Therapy for Sarcomas | Completed | USA | 0 |
NCT00902044 | Phase I | Fludarabine Cyclophosphamide HER2 sensitized T-cells | Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT01005797 | Phase I | Panobinostat + Sorafenib | Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers | Completed | USA | 0 |
NCT01010958 | Phase I | Valproic acid | Adjuvant Valproate for High Grade Sarcomas | Terminated | USA | 0 |
NCT01106872 | Phase Ib/II | Bevacizumab + Docetaxel + Gemcitabine + Valproic acid | Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas | Completed | USA | 0 |
NCT01154452 | Phase Ib/II | Vismodegib RO4929097 + Vismodegib RO4929097 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | Completed | USA | 0 |
NCT01189643 | Phase I | Bevacizumab + Irinotecan + Temozolomide | Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor | Active, not recruiting | USA | 0 |
NCT01294670 | Phase Ib/II | Etoposide + Vorinostat | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | Completed | USA | CAN | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | POL | ESP | 0 |
NCT01418001 | Phase Ib/II | Docetaxel + Gemcitabine + Pazopanib | Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) | Terminated | USA | 0 |
NCT01438554 | Phase I | Pazopanib + Trametinib | Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma | Completed | USA | 0 |
NCT01446809 | Phase I | Doxorubicin + Ifosfamide Doxorubicin + Ifosfamide + Pazopanib | Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01468922 | Phase I | Tivantinib Pazopanib | Pazopanib and ARQ 197 for Advanced Solid Tumors | Completed | USA | 0 |
NCT01518413 | Phase I | Irinotecan + Sorafenib | Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors | Completed | USA | 0 |
NCT01532687 | Phase II | Gemcitabine Gemcitabine + Pazopanib | Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01593748 | Phase II | Docetaxel + Gemcitabine Gemcitabine + Pazopanib | A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01625351 | Phase I | Fludarabine Melphalan Busulfan Alemtuzumab | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | Completed | USA | 0 |
NCT01643278 | Phase I | Dasatinib + Ipilimumab | Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic | Completed | USA | 0 |
NCT01695005 | Phase I | LY3039478 | A Study of LY3039478 in Participants With Advanced Cancer | Completed | USA | GBR | FRA | ESP | DNK | DEU | 0 |
NCT01719302 | Phase Ib/II | Docetaxel + Gemcitabine + Pazopanib | Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01719744 | Phase II | ENMD-2076 | Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | Completed | CAN | 0 |
NCT01746238 | Phase I | Bevacizumab + Doxorubicin | Bevacizumab/Doxorubicin/Radiation for Sarcoma | Active, not recruiting | USA | 0 |
NCT01755195 | Phase II | Cabozantinib | Cabozantinib for Adults With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT01879085 | Phase Ib/II | Gemcitabine Docetaxel Pegfilgrastim Vorinostat | Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | Completed | USA | 0 |
NCT01946529 | Phase II | Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine Sulfate Bevacizumab + Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Irinotecan + Sorafenib + Temozolomide + Temsirolimus + Vincristine Sulfate | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | Active, not recruiting | USA | 0 |
NCT01975519 | Phase I | Carotuximab + Pazopanib | A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02008877 | Phase Ib/II | Ganetespib + Sirolimus | A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST | Completed | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | POL | NLD | ITA | ISR | HUN | FRA | ESP | DNK | CAN | AUS | 2 |
NCT02050919 | Phase II | Epirubicin + Ifosfamide + Sorafenib | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02066181 | Phase III | Sorafenib | Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis | Completed | USA | CAN | 0 |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
NCT02173093 | Phase Ib/II | Aldesleukin + GD2Bi-aATC + Sargramostim | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | Unknown status | USA | 0 |
NCT02180698 | Phase I | GLA-SE | TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02180867 | Phase II | Pazopanib Doxorubicin + Ifosfamide | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS) | Active, not recruiting | USA | CAN | 1 |
NCT02192541 | Phase I | Aflibercept + Ganetespib | Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas | Terminated | USA | 0 |
NCT02267083 | Phase II | Camsirubicin | Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Recruiting | ITA | FRA | ESP | 0 |
NCT02300545 | Phase II | Pazopanib | Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy | Completed | USA | 0 |
NCT02319824 | Phase I | NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy | Completed | USA | 0 | |
NCT02323191 | Phase I | Atezolizumab + Emactuzumab | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02331251 | Phase Ib/II | Vinorelbine Pembrolizumab Irinotecan Doxorubicin Gemcitabine Docetaxel Nab-paclitaxel | Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | Terminated | USA | 0 |
NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Unknown status | USA | 0 |
NCT02357810 | Phase II | Pazopanib + Topotecan | Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas | Completed | USA | 0 |
NCT02359474 | Phase II | Trabectedin | Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin (HyperTET) | Active, not recruiting | DEU | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02406781 | Phase II | Cyclophosphamide + Pembrolizumab Cyclophosphamide + GLA-SE + Pembrolizumab | Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial (PEMBROSARC) | Unknown status | FRA | 0 |
NCT02423863 | Phase II | Poly ICLC | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol | Completed | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02451943 | Phase III | Olaratumab Doxorubicin | A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
NCT02453191 | Phase Ib/II | Talimogene laherparepvec | TVEC and Preop Radiation for Sarcoma | Completed | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02500797 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma | Completed | USA | 0 |
NCT02508038 | Phase I | Zoledronic acid Fludarabine + Melphalan Melphalan Tacrolimus anti-thymocyte globulin Mycophenolate mofetil | Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa | Recruiting | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | NLD | FRA | CAN | 0 |
NCT02558140 | Phase I | RG7386 | A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 0 |
NCT02574728 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors | Recruiting | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02584309 | Phase II | Dexrazoxane Doxorubicin + Olaratumab | Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | 0 |
NCT02584647 | Phase Ib/II | Pexidartinib + Sirolimus | Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) | Active, not recruiting | USA | 0 |
NCT02601209 | Phase Ib/II | Pazopanib Sapanisertib | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Terminated | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02630368 | Phase Ib/II | Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) | Unknown status | FRA | 0 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | POL | HRV | CAN | 0 |
NCT02636725 | Phase II | Axitinib + Pembrolizumab | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | Completed | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
NCT02640508 | Phase II | Eribulin + Lenvatinib | Eribulin and Lenvatinib in Advanced Solid Tumors | Completed | USA | 0 |
NCT02643303 | Phase Ib/II | Durvalumab + Poly ICLC Tremelimumab | A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers | Completed | USA | 0 |
NCT02659020 | Phase Ib/II | Olaratumab Docetaxel + Gemcitabine | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | Completed | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | AUS | 0 |
NCT02783599 | Phase I | Doxorubicin + Olaratumab | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | ESP | 0 |
NCT02784795 | Phase I | Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 | A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors | Completed | USA | FRA | ESP | DNK | 0 |
NCT02787642 | Phase I | Olaparib | A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (RADIOSARP) | Completed | FRA | 0 |
NCT02789228 | Phase I | MultiTAA-specific T cells | Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) | Active, not recruiting | USA | 0 |
NCT02795819 | Phase I | Pazopanib + REC-2282 | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Terminated | USA | 0 |
NCT02815995 | Phase II | Durvalumab + Tremelimumab | Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes | Completed | USA | 0 |
NCT02839694 | Phase I | Decitabine + Tetrahydrouridine Celecoxib + Decitabine + Tetrahydrouridine | Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy | Withdrawn | 0 | |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02879162 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours | Unknown status | CAN | 0 |
NCT02888665 | Phase Ib/II | Doxorubicin + Pembrolizumab | Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02900651 | Phase Ib/II | MAK683 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Terminated | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT02987959 | Phase II | Sapanisertib | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Terminated | USA | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Active, not recruiting | FRA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03042819 | Phase I | Doxorubicin + Selinexor | Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas | Completed | CAN | 0 |
NCT03056001 | Phase II | Doxorubicin + Pembrolizumab | Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma | Completed | USA | 0 |
NCT03056599 | Phase I | Pembrolizumab Avelumab Interferon gamma Olaratumab Trabectedin Nivolumab Gemcitabine Interferon alpha-2b Doxorubicin Atezolizumab Eribulin Ipilimumab Durvalumab Aldesleukin Bortezomib Docetaxel | Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma | Completed | USA | 0 |
NCT03069378 | Phase II | Pembrolizumab + Talimogene laherparepvec | A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03092323 | Phase II | Pembrolizumab | A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) | Active, not recruiting | USA | ITA | CAN | AUS | 0 |
NCT03116529 | Phase Ib/II | Durvalumab + Tremelimumab | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma (NEXIS) | Terminated | USA | 0 |
NCT03126591 | Phase I | Olaratumab + Pembrolizumab | A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | FRA | DNK | BEL | 0 |
NCT03138161 | Phase Ib/II | Ipilimumab + Nivolumab + Trabectedin | Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT03139331 | Phase I | Irinotecan + Pazopanib + Temozolomide | PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma | Completed | USA | 0 |
NCT03149120 | Phase II | Nivolumab Nivolumab + Pazopanib | Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | Withdrawn | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03168061 | Phase Ib/II | NC-6300 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | Unknown status | USA | 0 |
NCT03210714 | Phase II | Erdafitinib | Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03217266 | Phase I | KRT-232 | MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT03242382 | Phase II | Palbociclib | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) | Recruiting | ESP | 0 |
NCT03283696 | Phase I | Doxorubicin + Ifosfamide + Mesna + Olaratumab | A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Completed | USA | ITA | DEU | 0 |
NCT03307616 | Phase II | Ipilimumab + Nivolumab Nivolumab | Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma | Active, not recruiting | USA | 0 |
NCT03338959 | Phase Ib/II | Pembrolizumab | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | Completed | USA | 0 |
NCT03365791 | Phase II | Ieramilimab Spartalizumab | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | Completed | USA | 0 |
NCT03397186 | Phase II | Trabectedin | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | Withdrawn | USA | 0 |
NCT03414229 | Phase II | Epacadostat + Pembrolizumab | A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03441360 | Phase II | Eribulin | Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) | Completed | USA | 0 |
NCT03449108 | Phase II | Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Iovance Alliance: LN-145 Across Multiple Tumor Types | Active, not recruiting | USA | 0 |
NCT03449381 | Phase I | BI 907828 | This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) | Active, not recruiting | USA | SWE | POL | ISR | ESP | DNK | DEU | CAN | BEL | 2 |
NCT03449901 | Phase II | ADI-PEG 20 + Docetaxel + Gemcitabine | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma | Completed | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Completed | USA | AUS | 0 |
NCT03463408 | Phase I | Ipilimumab + Nivolumab | Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT03465592 | Phase Ib/II | Nivolumab | Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma | Recruiting | USA | 0 |
NCT03474094 | Phase II | Atezolizumab | Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune) | Recruiting | GBR | FRA | 0 |
NCT03474640 | Phase I | Toripalimab-tpzi | Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies | Completed | USA | 0 |
NCT03478462 | Phase I | CLR 131 | Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma | Active, not recruiting | USA | CAN | AUS | 0 |
NCT03504488 | Phase Ib/II | BA3021 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors | Active, not recruiting | USA | POL | GRC | ESP | 2 |
NCT03548428 | Phase II | Atezolizumab | Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Stereosarc) | Recruiting | FRA | 0 |
NCT03660930 | Phase Ib/II | Nab-rapamycin + Pazopanib | Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Patients With Nonadipocytic Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03670069 | Phase I | Itacitinib | Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas | Terminated | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03715933 | Phase I | INBRX-109 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Recruiting | USA | 0 |
NCT03719430 | Phase II | Doxorubicin + Olaratumab + Sotigalimab | APX005M, Doxorubicin, Olaratumab in Advanced Sarcoma | Active, not recruiting | USA | 0 |
NCT03727789 | Phase I | CBL0137 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Terminated | USA | 0 |
NCT03778996 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 | SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients (HopES) | Active, not recruiting | USA | 0 |
NCT03784014 | Phase III | Ceritinib Dabrafenib + Trametinib Capmatinib Durvalumab + Olaparib Nilotinib Futibatinib Trametinib Palbociclib Glasdegib Lapatinib | Molecular Profiling of Advanced Soft-tissue Sarcomas (MULTISARC) | Active, not recruiting | FRA | 0 |
NCT03793361 | Phase II | Regorafenib | Phase II Study of Regorafenib as Maintenance Therapy | Active, not recruiting | FRA | 0 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03838744 | Phase II | Olaparib + Trabectedin Trabectedin | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments. (TOMAS2) | Completed | ITA | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT03886311 | Phase II | Nivolumab + Talimogene laherparepvec + Trabectedin | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma (TNT) | Recruiting | USA | 0 |
NCT03899805 | Phase II | Eribulin + Pembrolizumab | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT03957096 | Phase I | SGN-CD47M | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03986606 | Phase I | PSB205 | A Study of PSB205 in Subjects With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT03993678 | Phase Ib/II | IP-001 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | Recruiting | CHE | 0 |
NCT03994627 | Expanded access | Olaratumab | Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma | Available | USA | ITA | HUN | GBR | ESP | CAN | BRA | AUT | 3 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Recruiting | USA | 0 |
NCT04040205 | Phase II | Abemaciclib | Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Recruiting | USA | 0 |
NCT04052971 | Phase Ib/II | ABN401 | To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation | Recruiting | AUS | 1 |
NCT04076579 | Phase II | Olaparib + Trabectedin | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT04095208 | Phase II | Nivolumab + Relatlimab Nivolumab | Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study (CONGRATS) | Recruiting | FRA | 0 |
NCT04095221 | Phase Ib/II | Irinotecan + Prexasertib + Temozolomide | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | Active, not recruiting | USA | 0 |
NCT04118166 | Phase II | Ipilimumab + Nivolumab | Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | AUS | 0 |
NCT04145349 | Phase Ib/II | Cyclophosphamide + Vinorelbine Cyclophosphamide + Ramucirumab + Vinorelbine | CAMFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor | Active, not recruiting | USA | ITA | GBR | ESP | DEU | AUS | 1 |
NCT04145622 | Phase Ib/II | Ifinatamab deruxtecan | Study of DS-7300a in Participants With Advanced Solid Malignant Tumors | Recruiting | USA | 1 |
NCT04149691 | Phase I | CPL304110 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | Recruiting | POL | 0 |
NCT04165330 | Phase Ib/II | Anlotinib + Nivolumab | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Active, not recruiting | USA | 0 |
NCT04199026 | Phase I | Irinotecan Doxorubicin Ifosfamide Temozolomide Temsirolimus Ganitumab Pazopanib Everolimus Vincristine Sulfate | Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma | Not yet recruiting | USA | 0 |
NCT04200443 | Phase II | Cabozantinib + Temozolomide | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04204941 | Phase III | Doxorubicin Doxorubicin + Tazemetostat | Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | Recruiting | USA | GBR | CAN | 1 |
NCT04205227 | Phase Ib/II | ENB003 + Pembrolizumab | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | Active, not recruiting | USA | AUS | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Active, not recruiting | FRA | 0 |
NCT04220229 | Phase Ib/II | Cabozantinib | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Terminated | USA | 0 |
NCT04242238 | Phase I | Avelumab + Vimseltinib | Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas | Active, not recruiting | USA | 0 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04273061 | Phase II | Atezolizumab | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity (CAPTIV-8) | Recruiting | CAN | 0 |
NCT04332874 | Phase II | Pembrolizumab | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Recruiting | USA | 0 |
NCT04420975 | Phase I | BO-112 + Nivolumab | Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04469530 | Phase II | Celecoxib + Cyclophosphamide + Etoposide + Sirolimus | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903) | Recruiting | USA | 0 |
NCT04478279 | Phase Ib/II | ST-101 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT04480502 | Phase II | Envafolimab + Ipilimumab Envafolimab | ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (ENVASARC) | Active, not recruiting | USA | GBR | 0 |
NCT04535713 | Phase II | Docetaxel + Doxorubicin + Gemcitabine + Nivolumab | Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | Recruiting | USA | 0 |
NCT04551430 | Phase II | Cabozantinib + Ipilimumab + Nivolumab Cabozantinib | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04577014 | Phase Ib/II | Docetaxel + Gemcitabine + Retifanlimab | INCMGA00012 (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04593758 | Phase Ib/II | CPI-613 + Hydroxychloroquine | To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613 (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue | Completed | USA | 0 |
NCT04595747 | Phase II | Rogaratinib | Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST) | Active, not recruiting | USA | 0 |
NCT04595994 | Phase I | Selinexor | Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma | Recruiting | ESP | 0 |
NCT04599062 | Phase Ib/II | Talimogene laherparepvec | TVEC and Preop Radiation for Sarcoma (8 ml Dose) | Active, not recruiting | USA | 0 |
NCT04648826 | Phase Ib/II | Azacitidine + Bintrafusp alfa | Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies | Withdrawn | USA | 0 |
NCT04650984 | Phase III | Doxorubicin + Onfekafusp alfa Doxorubicin | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma (FIBROSARC) | Recruiting | POL | ITA | FRA | ESP | DEU | 0 |
NCT04705818 | Phase II | Durvalumab + Tazemetostat | Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) | Recruiting | FRA | 0 |
NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Suspended | USA | 0 |
NCT04718675 | Phase I | KB-0742 | A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04725331 | Phase Ib/II | BT-001 BT-001 + Pembrolizumab | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | Recruiting | FRA | BEL | 0 |
NCT04733183 | Phase II | Dacarbazine Dacarbazine + Onfekafusp alfa | Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma (FLASH) | Recruiting | POL | ITA | FRA | ESP | DEU | 0 |
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT04811196 | Phase I | Selinexor | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | Active, not recruiting | CAN | 0 |
NCT04837677 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT04874311 | Phase II | Bintrafusp alfa + Doxorubicin Doxorubicin | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST) | Recruiting | FRA | 0 |
NCT04906876 | Phase II | Docetaxel + Elraglusib + Gemcitabine | 9-ING-41Combined With Chemotherapy in Adolescents and Adults | Withdrawn | USA | 0 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT04995003 | Phase I | HER2 CAR-T cells + Nivolumab Cyclophosphamide + Fludarabine + HER2 CAR-T cells + Pembrolizumab | HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma | Recruiting | USA | 0 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05043649 | Phase I | Camsirubicin + Pegfilgrastim | Camsirubicin + Pegfilgrastim to Determine MTD in ASTS | Terminated | USA | 0 |
NCT05093322 | Phase Ib/II | Gemcitabine + Surufatinib | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Completed | USA | 0 |
NCT05094804 | Phase Ib/II | Nivolumab + OR2805 OR2805 + Pembrolizumab OR2805 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With a PD-1 Inhibitor | Recruiting | USA | 0 |
NCT05100628 | Phase I | NOX66 Doxorubicin + NOX66 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma | Terminated | USA | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05114668 | Phase I | EVT801 | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | 0 |
NCT05116254 | Phase I | AZD1390 + Durvalumab AZD1390 | Sarcomas and DDR-Inhibition; a Combined Modality Study (SADDRIN-1) | Recruiting | NLD | 0 |
NCT05116800 | Phase II | Docetaxel + Elraglusib + Gemcitabine | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | Withdrawn | USA | 0 |
NCT05131386 | Phase II | Dexamethasone + Trabectedin | Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas (SYNERGIAS) | Recruiting | ESP | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT05180695 | Phase Ib/II | Pazopanib + Siremadlin | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas (AMPHISARC) | Recruiting | FRA | 0 |
NCT05229601 | Phase I | HFB301001 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Active, not recruiting | USA | ESP | 0 |
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |
NCT05253131 | Phase Ib/II | AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib | Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas | Not yet recruiting | USA | 0 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05333458 | Phase II | Atezolizumab + Selinexor Atezolizumab | Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma | Recruiting | USA | 0 |
NCT05415098 | Phase I | APG-5918 | Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05448820 | Phase Ib/II | Envafolimab + YH001 Doxorubicin + Envafolimab + YH001 | YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT05488366 | Phase I | Pembrolizumab | Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma | Recruiting | USA | 0 |
NCT05515575 | Phase II | Niraparib | A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA | Active, not recruiting | USA | 0 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Completed | USA | 1 |
NCT05580588 | Phase II | SPH4336 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | Terminated | USA | 0 |
NCT05621668 | Phase I | AttIL12 T-cells + Cyclophosphamide | A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma | Recruiting | USA | 0 |
NCT05625412 | Phase I | CC-90001 + Nivolumab Capecitabine + CC-90001 CC-90001 CC-90001 + Docetaxel | A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | ARG | 2 |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Withdrawn | USA | 0 |
NCT05688280 | Phase Ib/II | IP-001 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS (INJECTABL-1) | Recruiting | USA | GBR | FRA | DEU | CHE | 0 |
NCT05691491 | Phase Ib/II | M1774 + Temozolomide | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Recruiting | USA | 0 |
NCT05711615 | Phase I | Pegylated liposomal doxorubicin + Peposertib | Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Recruiting | USA | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05755113 | Phase II | Tigilanol tiglate | A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT05809830 | Phase Ib/II | Doxorubicin Doxorubicin + LB-100 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas (Enhancer) | Recruiting | ESP | 0 |
NCT05813327 | Phase Ib/II | ADI-PEG 20 + Ifosfamide + Mesna | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT05836571 | Phase II | Ipilimumab + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma | Recruiting | USA | CAN | 0 |
NCT05944237 | Phase Ib/II | Atezolizumab + HTL0039732 HTL0039732 | HTL0039732 in Participants With Advanced Solid Tumours | Recruiting | GBR | 0 |
NCT06021626 | Phase I | CRD3874 | A Study of CRD3874-SI in People With Sarcoma or Merkel Cell Cancer | Recruiting | USA | 0 |
NCT06047977 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + tumor infiltrating lymphocytes | Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Not yet recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Not yet recruiting | FRA | 0 |
NCT06090266 | Phase Ib/II | Cemiplimab + OR502 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Recruiting | USA | 0 |
NCT06092580 | Phase I | AWT020 | Phase 1 Study of AWT020 in Advanced Cancer | Recruiting | AUS | 0 |
NCT06128863 | Phase II | Eftilagimod alpha + Pembrolizumab | Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial (EFTISARC-NEO) | Recruiting | POL | 0 |
NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
NCT06217536 | Phase Ib/II | Lurbinectedin | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Withdrawn | 0 | |
NCT06239272 | Phase Ib/II | Selinexor Pazopanib Doxorubicin + Ifosfamide | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | AUS | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06290388 | Phase Ib/II | 23ME-01473 | Study of 23ME-01473 in Patients With Advanced Solid Malignancies | Terminated | USA | 0 |
NCT06308419 | Phase I | Gemcitabine + Nab-rapamycin | A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions | Recruiting | USA | 0 |
NCT06332274 | Phase III | Tislelizumab | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (UMBRELLA) | Not yet recruiting | FRA | 0 |
NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
NCT06416436 | Phase I | Atezolizumab | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | Not yet recruiting | USA | 0 |
NCT06422806 | Phase III | Doxorubicin Doxorubicin + Pembrolizumab | Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Recruiting | USA | 0 |
NCT06444815 | Phase I | VET3-TGI Pembrolizumab + VET3-TGI | A Study of VET3-TGI in Patients With Solid Tumors (STEALTH-001) | Recruiting | USA | 0 |
NCT06474676 | Phase I | AttIL12 T-cells Cyclophosphamide | T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic Soft Tissue and Bone Sarcoma Patients. | Not yet recruiting | USA | 0 |
NCT06514651 | Phase I | MAQ-001 Ipilimumab + MAQ-001 | MAQ-001 in Patients With Advanced Solid Tumors | Recruiting | FRA | 0 |
NCT06630325 | Phase II | Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | Not yet recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |
NCT06641908 | Phase I | M3554 | Anti-GD2 ADC M3554 in Advanced Solid Tumors | Recruiting | USA | FRA | BEL | 1 |
NCT06660810 | Phase I | Talimogene laherparepvec | Neoadjuvant Intralesional Injection of Talimogene Laherparepvec | Not yet recruiting | USA | 0 |